Sources of Funding: This study was initiated and funded by Zoetis Inc. (formerly Pfizer Animal Health), Madison, NJ, USA.
Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis
Version of Record online: 5 JUL 2013
© 2013 Zoetis Inc. Veterinary Dermatology published by John Wiley & Sons on behalf of the ESVD and the ACVD.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 24, Issue 5, pages 479–e114, October 2013
How to Cite
Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Martin, D. D., Walsh, K. F., Harfst, J. A., Follis, S. L., King, V. L., Boucher, J. F. and Stegemann, M. R. (2013), Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Veterinary Dermatology, 24: 479–e114. doi: 10.1111/vde.12047
Conflict of Interest: All authors are current or former employees of Zoetis Inc.
Apoquel is a registered trademark of Zoetis.
- Issue online: 11 SEP 2013
- Version of Record online: 5 JUL 2013
- Manuscript Accepted: 11 MAY 2013
- Pfizer Animal Health
- 1VPI® Pet Insurance website. Top 10 pet medical conditions of 2010. Available at: http://press.petinsurance.com/pressroom/02222011Pet_Conditions_2010.aspx. Accessed Dec 28, 2012.
- 3Pruritic dermatitis. In: Beynon P, ed. A Colour Handbook of Skin Diseases of the Dog and Cat. 2nd edn. London: Manson Publishing, 2009; 35–37., , .
- 6Dermatologic therapy. In: Muller and Kirk's Small Animal Dermatology, 6th edition. Philadelphia: W.B. Saunders Co., 2001; 207–274., , .
- 9Glucocorticoid agents, general information. Veterinary drug handbook. 4th edn. Ames, IA: Blackwell Publishing; 2002; 387–389..
- 12Skin immune system and allergic skin diseases. In: Muller and Kirk's Small Animal Dermatology, 6th edition. Philadelphia, PA: W.B. Saunders Co., 2001; 543–666., , .
- 14Comparison of the janus kinase (JAK) inhibitor, oclacitinib, and prednisolone in canine models of pruritus. Vet Dermatol 2012; 23(Suppl 1): 38 (abstract)., , et al.
- 19International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH), Good Clinical Practice Website. Available at: http://www.vichsec.org/en/topics.htm. Accessed Dec 28, 2012.
- 21Single and multiple dose pharmacokinetics of oclacitinib maleate in the dog. In: Proceedings of the American Academy of Veterinary Pharmacology and Therapeutics, Biennial Meeting. Potomac, MD, USA. 2013 (Abstract #23)., , et al.
- 32Oclacitinib for the treatment of pruritus and lesions associated with canine flea-allergic dermatitis. Vet Dermatol 2012; 23(Suppl 1): 38–39 (abstract)., , et al.
- 33Efficacy and safety of oclacitinib compared to placebo for the control of atopic dermatitis in client-owned dogs. Vet Dermatol 2013; 24: 295 (abstract)., , et al.